Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Description

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Official source

Eligible beneficiaries

• For profit organizations other than small businesses
• Public housing authorities/Indian housing authorities
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Native American tribal governments (Federally recognized)
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• Public and State controlled institutions of higher education
• Independent school districts
• City or township governments
• State governments
• Special district governments
• County governments
• Small businesses
• Native American tribal organizations (other than Federally recognized tribal governments)
• Others (see text field entitled "Additional Information on Eligibility" for clarification)